Taysha Gene Therapies TSHA
NASDAQ TSHA
$4.87 -0.12 (-2.40%)
At close: Sep 30, 2026 · 4:00 PM EDT

Taysha Gene Therapies (TSHA) Total Non-Current Liabilities (2020 - 2026)

Updated

Taysha Gene Therapies (TSHA) recorded Total Non-Current Liabilities of $81.53 million in Q2 2026, down 2.0% from $83.21 million a year earlier and down 6.1% from the prior quarter.

Analysis

Taysha Gene Therapies (TSHA) Total Non-Current Liabilities (2020 - 2026) Analysis & Trends

At the end of FY2025, Taysha Gene Therapies reported Total Non-Current Liabilities of $94.83 million, up 8.3% from FY2024.

  • Annual Total Non-Current Liabilities has a five-year compound annual growth rate of 67.8% (FY2020 to FY2025).
  • Across earlier years, Total Non-Current Liabilities came in at $87.53 million in FY2024 (-9.0%), $96.22 million in FY2023 (-20.6%), $121.2 million in FY2022 (+5.5%) and $114.84 million in FY2021.
  • The Q2 2026 figure is the lowest quarterly Total Non-Current Liabilities since Q2 2021.
  • On a year-over-year basis, Total Non-Current Liabilities rose in three of the last eight quarters, with an average decline of 9.6%.
  • Peak year-over-year performance for Total Non-Current Liabilities in the last five years was growth of 489.4% in Q1 2022, against a decline of 62.6% in Q3 2024 at the low end.
  • Per Business Quant, the preceding three quarters came in at $86.83 million (Q1 2026), $94.83 million (Q4 2025) and $95.99 million (Q3 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Non-Current Liabilities (Qtr)
1 Johnson & Johnson 645.01 Bn 563.54 Bn 17.26 Bn 105.99 Bn
2 AbbVie 465.23 Bn 438.39 Bn 12.70 Bn 106.45 Bn
3 Merck 368.40 Bn 322.83 Bn 12.21 Bn 80.25 Bn
4 Novartis Ag 278.02 Bn 233.89 Bn 11.24 Bn 48.34 Bn
5 Astrazeneca 254.57 Bn 228.13 Bn 12.86 Bn -967.00 Mn
6 Amgen 229.02 Bn 184.42 Bn 7.24 Bn 81.11 Bn
7 Gilead Sciences 187.74 Bn 161.85 Bn 6.22 Bn 36.04 Bn
8 Pfizer 163.75 Bn 110.70 Bn 10.94 Bn 100.86 Bn
9 Vertex Pharmaceuticals 133.45 Bn 105.45 Bn 2.84 Bn 5.92 Bn
10 Taysha Gene Therapies 1.62 Bn 1.62 Bn - 81.53 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 81.53 Mn
Mar 31, 2026 86.83 Mn
Dec 31, 2025 94.83 Mn
Sep 30, 2025 95.99 Mn
Jun 30, 2025 83.21 Mn
Mar 31, 2025 82.10 Mn
Dec 31, 2024 87.53 Mn
Sep 30, 2024 90.06 Mn
Jun 30, 2024 90.15 Mn
Mar 31, 2024 97.65 Mn
Dec 31, 2023 96.22 Mn
Sep 30, 2023 241.05 Mn
Jun 30, 2023 114.74 Mn
Mar 31, 2023 112.54 Mn
Dec 31, 2022 121.20 Mn
Sep 30, 2022 96.83 Mn
Jun 30, 2022 106.35 Mn
Mar 31, 2022 111.74 Mn
Dec 31, 2021 114.84 Mn
Sep 30, 2021 97.63 Mn
API Access

Taysha Gene Therapies Total Non-Current Liabilities API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=total-non-current-liabilities&ticker=TSHA&period=max&api_key=YOUR_API_KEY